Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4242
Source ID: NCT03462017
Associated Drug: Sar247799
Title: Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Microvascular Coronary Artery Disease
Interventions: DRUG: SAR247799|DRUG: Placebo|DRUG: Sildenafil|DRUG: Acetylcholine
Outcome Measures: Primary: Change in Flow Mediated Dilation (FMD), Absolute change from baseline in the % FMD index of the brachial artery, Baseline to Days 14, 21, 28, 35, and 42 | Secondary: Microvascular reactivity, Change from baseline in peak flow induced by acetylcholine iontophoresis measured using Laser Doppler perfusion monitoring, Baseline to Days 14, 21, 28, 35, and 42|Number of adverse events, Number of participants with adverse events, Up to Day 42|Assessment of pharmacokinetic (PK) parameter: Cmax, Cmax: Maximum plasma concentration observed, Days 1, 2, 3, 7, and 14|Assessment of PK parameter: Ctrough, Ctrough: Plasma concentration observed just before treatment administration during repeated dosing, Days 1, 2, 3, 7, and 14|Assessment of PK parameter: tmax, tmax: Time to reach Cmax, Days 1, 2, 3, 7, and 14|Assessment of PK parameter: AUC0-24, AUC0-24: Area under the plasma concentration versus time curve over the dosing interval (24h), Days 1, 2, 3, 7, and 14
Sponsor/Collaborators: Sponsor: Sanofi
Gender: ALL
Age: ADULT
Phases: PHASE1
Enrollment: 54
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE
Start Date: 2018-03-07
Completion Date: 2018-12-22
Results First Posted:
Last Update Posted: 2022-04-25
Locations: Investigational Site Number 2760002, Mainz, 55116, Germany|Investigational Site Number 2760001, Neuss, 41460, Germany
URL: https://clinicaltrials.gov/show/NCT03462017